SCHEMBL5113248

SCHEMBL5113248

CCSc1nc(Cl)c2ccccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
MAPK1 P28482 1/20 0.56
ELANE P08246 1/20 0.46
MAPT P10636 4/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
XBP1 P17861 1/20 0.44
HTT P42858 1/20 0.44
PAX8 Q06710 1/20 0.44
ATM Q13315 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
PDE7A Q13946 1/20 0.43
ABCB1 P08183 2/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PDE10A Q9Y233 1/20 0.42
POLB P06746 1/20 0.42
METAP1 P53582 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14140209 0.81 KDM4E (0.59) KDM4EMAPK1ELANEMAPTNPC1
SCHEMBL8483152 0.80 KDM4E (0.59) KDM4EMAPTLMNAHTTMAOA
SCHEMBL31392367 0.80 KDM4E (0.59) KDM4EMAPTLMNAHTTMAOA
SCHEMBL859288 0.77 ALDH1A1 (0.54) KDM4EMAPK1MAPTLMNAHTT
SCHEMBL9312972 0.75 LMNA (0.47) MAPK1MAPTLMNANPC1RAB9A
SCHEMBL28035988 0.75 KDM4E (0.51) KDM4EMAPTLMNAHTTMAOA
SCHEMBL9173175 0.74 ALDH1A1 (0.55) KDM4EMAPK1ELANEMAPTLMNA
SCHEMBL4866091 0.73 APP (0.57) KDM4EMAPK1ELANEMAPTLMNA
SCHEMBL4863793 0.72 APP (0.62) KDM4EMAPTLMNARAB9AATM
SCHEMBL4863823 0.72 ABCB1 (0.43) KDM4EMAPK1ELANEMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R KDM4E 1731/4885MAPK1 513/4885ELANE 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.